Buy CME

Logo for stock CME (CME)

Amount

£
GBP

Latest price

$260.94
(£1.00 = $1.295)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$93.634B

P/E ratio

26.86

EPS

$9.672

Beta

0.45

Dividend rate

$10.40

Dividend yield

4.00%

About

CME Group Inc. provides a derivatives marketplace. The Company enables clients to trade futures, options, cash and over the counter (OTC) markets, optimize portfolios, and analyze data. It exchanges offer a range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange (FX), energy, agricultural products and metals. It offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and FX trading on the EBS platform. In addition, it operates central counterparty clearing provider, CME Clearing. Its products provide a means for hedging, speculation and asset allocation related to the risks associated with, among other things, interest rate sensitive instruments, and changes in the prices of agricultural, energy and metal commodities. It provides clearing and settlement services for a range of exchange-traded futures and options on futures contracts and OTC derivatives.

CEO

Hon. Terrence A. (Terry) Duffy

Employees

3,760

Sector

Finance

Company HQ

CHICAGO, United States of America

News

Logo for news article #0 (CME Group Inc. Announces First-Quarter 2025 Earnings Release, Conference Call)

CME Group Inc. Announces First-Quarter 2025 Earnings Release, Conference Call

CHICAGO , March 12, 2025 /PRNewswire/ -- CME Group Inc. will announce earnings for the first quarter of 2025 before the markets open on Wednesday, April 23, 2025. Written highlights for the quarter will be posted on the company's website at 6:00 a.m.

PRNewsWire

March 12, 2025

Logo for news article #1 (CME Group Rising on Record Revenue)

CME Group Rising on Record Revenue

Highest volumes on record lift shares of derivatives marketplace leader CME Group, Inc. (CME).

FXEmpire

March 12, 2025

Logo for news article #2 (CME Group (CME) Is Up 0.32% in One Week: What You Should Know)

CME Group (CME) Is Up 0.32% in One Week: What You Should Know

Does CME Group (CME) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research

March 11, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.